» Articles » PMID: 19431148

IL-8 Induces Exocytosis of Arginase 1 by Neutrophil Polymorphonuclears in Nonsmall Cell Lung Cancer

Overview
Journal Int J Cancer
Specialty Oncology
Date 2009 May 12
PMID 19431148
Citations 88
Authors
Affiliations
Soon will be listed here.
Abstract

Arginase 1 (ARG1) inhibits T-cell proliferation by degrading extracellular arginine, which results in decreased responsiveness of T cells to CD3/TCR stimulation. In humans, ARG1 is stored in inactive form within granules of polymorphonuclear neutrophils (PMNs) and gets activated on release. We studied the role of PMNs-related ARG1 activity in nonsmall cell lung cancer (NSLC), in which tumor-infiltrating lymphocytes showed reduced proliferation in response to CD3/TCR triggering. Patients with NSCLC had increased ARG1 plasma levels as compared to healthy controls. Furthermore, immunohistochemistry showed that tumor-infiltrating PMNs display reduced intracellular ARG1, in comparison to intravascular or peritumoral PMNs, suggesting a role of tumor microenvironment in ARG1 release. Indeed, supernatants of NSCLC cell lines induced exocytosis of ARG1 from PMNs. All (4/4) NSCLC cell lines and all (7/7) CD14- cell samples from NSCLC expressed interleukin (IL)-8 mRNA, whereas TNFalpha mRNA was expressed by 1 cell line and by 2 tumor specimens. Furthermore, all NSCLC cell lines secreted immunoreactive IL-8, albeit at different levels. IL-8 was as effective as TNFalpha in triggering ARG1 release and the 2 cytokines acted synergistically. Secreted ARG1 was biologically active and catabolized extracellular arginine. The supernatant of IL-8 gene-silenced NSCLC cells did not mediate ARG1 release by PMNs. Altogether these findings demonstrate a role of IL-8 in ARG1 exocytosis by PMNs and indicate that, due at least in part to IL-8 secreted by NSCLC cells, PMNs infiltrating NSCLC release ARG1. This phenomenon could contribute to local immune suppression.

Citing Articles

The post-orchiectomy systemic inflammatory index is associated with tumor characteristics in clinical stage I germ cell tumors.

Lesko P, Mego M Front Oncol. 2025; 15:1490264.

PMID: 40066096 PMC: 11891062. DOI: 10.3389/fonc.2025.1490264.


Neutrophil Engulfment in Cancer: Friend or Foe?.

Lu T, Li W Cancers (Basel). 2025; 17(3).

PMID: 39941753 PMC: 11816126. DOI: 10.3390/cancers17030384.


Unraveling impact and potential mechanisms of baseline pain on efficacy of immunotherapy in lung cancer patients: a retrospective and bioinformatic analysis.

Zhang Z, Zhao W, Lv C, Wu Z, Liu W, Chang X Front Immunol. 2024; 15:1456150.

PMID: 39654896 PMC: 11625792. DOI: 10.3389/fimmu.2024.1456150.


Neutrophil chemotaxis score and chemotaxis-related genes have the potential for clinical application to prognosticate the survival of patients with tumours.

Yang Y, Yang J, Li L, Shao Y, Liu L, Sun B BMC Cancer. 2024; 24(1):1244.

PMID: 39379856 PMC: 11463147. DOI: 10.1186/s12885-024-12993-1.


Emergence of dysfunctional neutrophils with a defect in arginase-1 release in severe COVID-19.

Dwivedi A, Ui Mhaonaigh A, Carroll M, Khosravi B, Batten I, Ballantine R JCI Insight. 2024; 9(17).

PMID: 39253969 PMC: 11385094. DOI: 10.1172/jci.insight.171659.